Clinical Trials Logo

Clinical Trial Summary

Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term disability in infants born at term in the western world, affecting about 1-4 per 1.000 life births and consequently about 5-20.000 infants per year in Europe. Hypothermic treatment became the only established therapy to improve outcome after perinatal hypoxic-ischemic insults. Despite hypothermia and neonatal intensive care, 45-50% of affected children die or suffer from long-term neurodevelopmental impairment. Additional neuroprotective interventions, beside hypothermia, are warranted to further improve their outcome. Allopurinol is a xanthine oxidase inhibitor and reduces the production of oxygen radicals and brain damage in experimental, animal, and early human studies of ischemia and reperfusion. This project aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to near-term infants with HIE in addition to hypothermic treatment.


Clinical Trial Description

During labour and childbirth various events (such as placental abruption, uterine rupture, umbilical cord complications etc.) may result in impaired oxygenation and/or perfusion of the newborn brain which may result in brain injury termed "hypoxic-ischemic encephalopathy" (HIE). HIE is associated with development of long-term motor, cognitive, and neurosensory and memory disability and is one of the fundamental problems in perinatal medicine affecting about 5,000-20,000 infants/year in Europe (or 1-4/1000 live births in western societies) and approximately 1 million infants/year worldwide. In term infants with perinatal asphyxia and postnatal HIE, brain injury predominantly originates in the immediate perinatal period (in contrast to a more distant prenatally acquired brain injury) as indicated by the lack of already established brain injury on early postnatal MRI. Consequently, brain injury in this population may potentially be ameliorated by postnatal pharmacological interventions. The most common motor disability resulting from HIE is "cerebral palsy", the other major adverse outcome is cognitive disability, which prevents affected patients to lead their lives independently (without assistance and/or financial support). The single major cause of HIE is a perinatal hypoxic/ischemic event (perinatal asphyxia). This hypoxic insult can cause immediate (necrosis) and delayed death (apoptosis) of (especially neuronal) cells, the latter responsible for a substantial amount of HIE-associated permanent brain damage. Whereas no intervention is known to prevent necrosis, the delayed cell death by apoptosis can be reduced by therapeutic interventions: Apoptosis is in part caused by secondary energy failure which can be reduced by hypothermic treatment. Apoptosis is also caused by xanthine oxidase-mediated production of cytotoxic oxygen radicals during reperfusion, and there is evidence that allopurinol, a xanthine-oxidase inhibitor, reduces delayed cell death in animal models of perinatal asphyxia and ischemia/reperfusion. Allopurinol prevents adenosine degradation, oxygen radical formation, preserves NMDA receptor integrity, and consequently may reduce brain injury in HIE by several mechanisms of action which are independent from the proven beneficial effect of hypothermic treatment on cellular energy metabolism. An additional beneficial (or even synergistic?) effect of allopurinol in addition to hypothermia can therefore be expected. As no safety concerns were known at the start of this study regarding administration of even high doses of Allopurinol to neonates a phase III study was planned instead of a pilot study or an adaptive design. Close follow-up of MR-imaging along with reporting of all safety relevant data to a Data Monitoring Committee (which includes experts for brain imaging not otherwise involved in the study) ensures patients' safety. Primary objective of this study is to evaluate whether newborns with asphyxia and early clinical signs of hypoxic ischemic encephalopathy will benefit from early administered Allopurinol compared to placebo, both in addition to standard of care, regarding long-term follow-up such as severe neurodevelopmental impairment or death at two years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03162653
Study type Interventional
Source University Hospital Tuebingen
Contact Oldershausen Gabriele
Phone +49 7071 29-86176
Email Albino@med.uni-tuebingen.de
Status Recruiting
Phase Phase 3
Start date March 25, 2018
Completion date January 31, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05936112 - Quantification of Fecal Calprotectin Concentration Difference Between Infants Aged Under 4 Months Old Suffering From Functional Gastrointestinal Disorders (FGID) and Infants Aged Under 4 Months Old Free From Disorders : a Transversal Case-control Monocentric Study N/A
Not yet recruiting NCT05954975 - Baby Sickness Evaluation
Completed NCT02968628 - Effect of Maternal Diabetes on Brain Development, as Measured by Neonatal Electroencephalogram (EEG)
Not yet recruiting NCT00994149 - Diazoxide In the Management Of Hypoglycemic Neonates Phase 2/Phase 3
Completed NCT03571932 - Assessment of Family Planning and Immunization Service Integration in Liberia
Completed NCT02865772 - Lamellar Body Counts on Gastric Aspirate in Healthy Term Newborns N/A
Completed NCT03535311 - Estimating Insertion Length of Umbilical Catheters in Newborn Infants
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Recruiting NCT06139809 - Noninvasive Positive Pressure Ventilation During Neonatal Nasal Intubation N/A
Not yet recruiting NCT06267508 - Increasing Neonatal HIV Test and Treat to Maximize the Long-Term Impact on Infant Health and Novel Infant Antiretroviral Treatment
Completed NCT02701920 - HeartLight: Heart Rate Monitoring for Newborn Resuscitation
Completed NCT01124331 - Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis N/A
Active, not recruiting NCT04354220 - Capnography Monitoring in Ventilated Children
Recruiting NCT05793723 - Long-term Respiratory Complications in Infants With Perinatal COVID-19
Completed NCT03404284 - Assessment of Family Planning and Immunization Service Integration in Malawi N/A
Completed NCT01954056 - Hydrocortisone for Term Hypotension Phase 3
Not yet recruiting NCT06255886 - Treatment of Gastroesophageal Reflux Disease in Infants Phase 4
Completed NCT02434380 - Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes Phase 3
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2